BiotechTV
@biotechtv.bsky.social
News, stories, and educational videos about the biotechnology sector. Bringing biotech to life. 📺
𝐓𝐡𝐞 𝐒𝐭𝐮𝐝𝐢𝐨 𝐚𝐭 𝐊𝐞𝐧𝐝𝐚𝐥𝐥 𝐒𝐪𝐮𝐚𝐫𝐞: Do you have unique expertise on a topic in biotech? Are you doing cutting edge research at your company or lab? If so, BiotechTV and @massbio.bsky.social want to help broadcast your story to the world.
July 31, 2025 at 11:05 PM
𝐓𝐡𝐞 𝐒𝐭𝐮𝐝𝐢𝐨 𝐚𝐭 𝐊𝐞𝐧𝐝𝐚𝐥𝐥 𝐒𝐪𝐮𝐚𝐫𝐞: Do you have unique expertise on a topic in biotech? Are you doing cutting edge research at your company or lab? If so, BiotechTV and @massbio.bsky.social want to help broadcast your story to the world.
BiotechTV visited former NIH Director and Co-Founder of ModeX, Elias Zerhouni, yesterday. He has new memoir out covering his extensive career in medicine, academia, government, and industry. It may have some lessons for today’s times.
See the interview: www.biotechtv.com/post/modex-t...
See the interview: www.biotechtv.com/post/modex-t...
July 31, 2025 at 1:58 PM
BiotechTV visited former NIH Director and Co-Founder of ModeX, Elias Zerhouni, yesterday. He has new memoir out covering his extensive career in medicine, academia, government, and industry. It may have some lessons for today’s times.
See the interview: www.biotechtv.com/post/modex-t...
See the interview: www.biotechtv.com/post/modex-t...
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐓𝐨𝐮𝐫: BiotechTV visited the new offices of @seaporttx.bsky.social today and was given a tour by Founder & CEO @daphnezohar.bsky.social
July 21, 2025 at 11:46 PM
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐓𝐨𝐮𝐫: BiotechTV visited the new offices of @seaporttx.bsky.social today and was given a tour by Founder & CEO @daphnezohar.bsky.social
𝐀𝐫𝐨𝐮𝐧𝐝 𝐊𝐞𝐧𝐝𝐚𝐥𝐥: Over the weeks and months ahead, BiotechTV is excited to present a new weekly series that will highlight the world capital of biotech, Kendall Square. Please tune in on X, Instagram, and TikTok.
July 17, 2025 at 1:14 AM
𝐀𝐫𝐨𝐮𝐧𝐝 𝐊𝐞𝐧𝐝𝐚𝐥𝐥: Over the weeks and months ahead, BiotechTV is excited to present a new weekly series that will highlight the world capital of biotech, Kendall Square. Please tune in on X, Instagram, and TikTok.
𝐎𝐯𝐞𝐫𝐭𝐢𝐦𝐞: Successful biotech entrepreneur Ron Renaud shares his advice for biotech operators today, and gives his take on the state of the industry.
July 16, 2025 at 7:09 PM
𝐎𝐯𝐞𝐫𝐭𝐢𝐦𝐞: Successful biotech entrepreneur Ron Renaud shares his advice for biotech operators today, and gives his take on the state of the industry.
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: KalVista’s CEO discusses today's FDA approval and commercial launch of Ekterly, the first oral therapy for treating hereditary angioedema (HAE) attacks.
Full video: www.biotechtv.com/post/kalvist...
Full video: www.biotechtv.com/post/kalvist...
July 7, 2025 at 10:07 PM
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: KalVista’s CEO discusses today's FDA approval and commercial launch of Ekterly, the first oral therapy for treating hereditary angioedema (HAE) attacks.
Full video: www.biotechtv.com/post/kalvist...
Full video: www.biotechtv.com/post/kalvist...
𝐐𝐮𝐢𝐜𝐤 𝐓𝐚𝐤𝐞: Today it was announced that AbbVie will be acquiring the in-vivo CAR-T company Capstan Therapeutics for up to $2.1B. Brad Loncar shares his take on what the news could mean for the broader biotech sector.
June 30, 2025 at 5:10 PM
𝐐𝐮𝐢𝐜𝐤 𝐓𝐚𝐤𝐞: Today it was announced that AbbVie will be acquiring the in-vivo CAR-T company Capstan Therapeutics for up to $2.1B. Brad Loncar shares his take on what the news could mean for the broader biotech sector.
𝐎𝐟𝐟-𝐓𝐚𝐫𝐠𝐞𝐭 𝐄𝐟𝐟𝐞𝐜𝐭𝐬: Matt Gline speaks with Philip Ross, one of the most experienced and successful bankers in healthcare, about the M&A landscape and his decision to join Jefferies last year.
Full video: www.biotechtv.com/post/off-tar...
Full video: www.biotechtv.com/post/off-tar...
June 30, 2025 at 12:28 PM
𝐎𝐟𝐟-𝐓𝐚𝐫𝐠𝐞𝐭 𝐄𝐟𝐟𝐞𝐜𝐭𝐬: Matt Gline speaks with Philip Ross, one of the most experienced and successful bankers in healthcare, about the M&A landscape and his decision to join Jefferies last year.
Full video: www.biotechtv.com/post/off-tar...
Full video: www.biotechtv.com/post/off-tar...
𝐂𝐀𝐑-𝐓 𝐋𝐨𝐠𝐢𝐜-𝐆𝐚𝐭𝐢𝐧𝐠: ArsenalBio CEO Ken Drazan describes the idea of logic-gating, which might allow CAR-T therapies to work in solid tumors when targeting more than one antigen is needed.
June 29, 2025 at 11:27 PM
𝐂𝐀𝐑-𝐓 𝐋𝐨𝐠𝐢𝐜-𝐆𝐚𝐭𝐢𝐧𝐠: ArsenalBio CEO Ken Drazan describes the idea of logic-gating, which might allow CAR-T therapies to work in solid tumors when targeting more than one antigen is needed.
𝐑𝐍𝐀 𝐄𝐝𝐢𝐭𝐢𝐧𝐠: Jones Research Senior Healthcare Research Analyst Catherine Novack discusses the latest in the RNA editing space.
Full interview: www.biotechtv.com/post/catheri...
Full interview: www.biotechtv.com/post/catheri...
June 28, 2025 at 8:28 PM
𝐑𝐍𝐀 𝐄𝐝𝐢𝐭𝐢𝐧𝐠: Jones Research Senior Healthcare Research Analyst Catherine Novack discusses the latest in the RNA editing space.
Full interview: www.biotechtv.com/post/catheri...
Full interview: www.biotechtv.com/post/catheri...
𝐒𝐈𝐓𝐂 𝐚𝐭 𝐍𝐘𝐒𝐄: Today we attended the @sitcancer.bsky.social Strategic Meeting at NYSE.
Zhen Su tells us what the meeting is about and why he is excited about IO today.
Zhen Su tells us what the meeting is about and why he is excited about IO today.
June 27, 2025 at 10:39 PM
𝐒𝐈𝐓𝐂 𝐚𝐭 𝐍𝐘𝐒𝐄: Today we attended the @sitcancer.bsky.social Strategic Meeting at NYSE.
Zhen Su tells us what the meeting is about and why he is excited about IO today.
Zhen Su tells us what the meeting is about and why he is excited about IO today.
𝐀𝐧𝐚𝐥𝐲𝐬𝐭 𝐓𝐡𝐮𝐫𝐬𝐝𝐚𝐲𝐬: William Blair analyst Andy Hsieh puts odds on Lilly’s pill orforglipron succeeding in obesity after seeing diabetes data at #ADA25 in Chicago.
Hear all of his ADA takeaways here: www.biotechtv.com/post/andy-hs...
Hear all of his ADA takeaways here: www.biotechtv.com/post/andy-hs...
June 26, 2025 at 3:23 PM
𝐀𝐧𝐚𝐥𝐲𝐬𝐭 𝐓𝐡𝐮𝐫𝐬𝐝𝐚𝐲𝐬: William Blair analyst Andy Hsieh puts odds on Lilly’s pill orforglipron succeeding in obesity after seeing diabetes data at #ADA25 in Chicago.
Hear all of his ADA takeaways here: www.biotechtv.com/post/andy-hs...
Hear all of his ADA takeaways here: www.biotechtv.com/post/andy-hs...
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Checking in with the co-founders of Amylyx, which now has one program in pivotal, another that may start soon, and earlier stage clinical programs that will have data this year. $AMLX
Full video: www.biotechtv.com/post/amylyx-...
Full video: www.biotechtv.com/post/amylyx-...
June 26, 2025 at 2:06 AM
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Checking in with the co-founders of Amylyx, which now has one program in pivotal, another that may start soon, and earlier stage clinical programs that will have data this year. $AMLX
Full video: www.biotechtv.com/post/amylyx-...
Full video: www.biotechtv.com/post/amylyx-...
𝐓𝐡𝐞 𝐒𝐭𝐮𝐝𝐢𝐨 𝐚𝐭 𝐊𝐞𝐧𝐝𝐚𝐥𝐥 𝐒𝐪𝐮𝐚𝐫𝐞: Biotech veteran @artkrieg.bsky.social explains the science behind his newest immunotherapy company, Zola Therapeutics, which uses both RNA and DNA agonists delivered in an LNP.
Full video: www.biotechtv.com/post/zola-th...
Full video: www.biotechtv.com/post/zola-th...
April 22, 2025 at 10:00 PM
𝐓𝐡𝐞 𝐒𝐭𝐮𝐝𝐢𝐨 𝐚𝐭 𝐊𝐞𝐧𝐝𝐚𝐥𝐥 𝐒𝐪𝐮𝐚𝐫𝐞: Biotech veteran @artkrieg.bsky.social explains the science behind his newest immunotherapy company, Zola Therapeutics, which uses both RNA and DNA agonists delivered in an LNP.
Full video: www.biotechtv.com/post/zola-th...
Full video: www.biotechtv.com/post/zola-th...
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: After switching to a new GalNAc-LNP delivery vehicle a year ago, Verve Therapeutics today announced the initial safety and efficacy data from its VERVE-102 PCSK9 based editor.
Full video: www.biotechtv.com/post/verve-t...
Full video: www.biotechtv.com/post/verve-t...
April 14, 2025 at 12:33 PM
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: After switching to a new GalNAc-LNP delivery vehicle a year ago, Verve Therapeutics today announced the initial safety and efficacy data from its VERVE-102 PCSK9 based editor.
Full video: www.biotechtv.com/post/verve-t...
Full video: www.biotechtv.com/post/verve-t...
𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐂𝐄𝐎 𝐒𝐢𝐬𝐭𝐞𝐫𝐡𝐨𝐨𝐝: x4 Pharmaceuticals' CEO Paula Ragan on her career and running a commercial stage company in the rare disease space.
Full video: www.biotechtv.com/post/paula-r...
Full video: www.biotechtv.com/post/paula-r...
April 8, 2025 at 9:31 PM
𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐂𝐄𝐎 𝐒𝐢𝐬𝐭𝐞𝐫𝐡𝐨𝐨𝐝: x4 Pharmaceuticals' CEO Paula Ragan on her career and running a commercial stage company in the rare disease space.
Full video: www.biotechtv.com/post/paula-r...
Full video: www.biotechtv.com/post/paula-r...
𝐓𝐡𝐞 𝐒𝐭𝐮𝐝𝐢𝐨 𝐚𝐭 𝐊𝐞𝐧𝐝𝐚𝐥𝐥 𝐒𝐪𝐮𝐚𝐫𝐞: Elias Zerhouni and Andy Plump discuss the future of multispecific biologics. Plus, career advice, biotech compared to pharma, and more.
Full video: www.biotechtv.com/post/elias-z...
Full video: www.biotechtv.com/post/elias-z...
April 7, 2025 at 5:10 PM
𝐓𝐡𝐞 𝐒𝐭𝐮𝐝𝐢𝐨 𝐚𝐭 𝐊𝐞𝐧𝐝𝐚𝐥𝐥 𝐒𝐪𝐮𝐚𝐫𝐞: Elias Zerhouni and Andy Plump discuss the future of multispecific biologics. Plus, career advice, biotech compared to pharma, and more.
Full video: www.biotechtv.com/post/elias-z...
Full video: www.biotechtv.com/post/elias-z...
𝐀𝐧𝐚𝐥𝐲𝐬𝐭 𝐓𝐡𝐮𝐫𝐬𝐝𝐚𝐲𝐬: Stifel's Alex Thompson updates us on the latest news and upcoming catalysts in the I&I space.
$ARGX $IMVT $ANAB $APGE $DNTH $VRDN
Full video: www.biotechtv.com/post/alex-th...
$ARGX $IMVT $ANAB $APGE $DNTH $VRDN
Full video: www.biotechtv.com/post/alex-th...
April 3, 2025 at 11:38 PM
𝐀𝐧𝐚𝐥𝐲𝐬𝐭 𝐓𝐡𝐮𝐫𝐬𝐝𝐚𝐲𝐬: Stifel's Alex Thompson updates us on the latest news and upcoming catalysts in the I&I space.
$ARGX $IMVT $ANAB $APGE $DNTH $VRDN
Full video: www.biotechtv.com/post/alex-th...
$ARGX $IMVT $ANAB $APGE $DNTH $VRDN
Full video: www.biotechtv.com/post/alex-th...
𝐀𝐧𝐠𝐥𝐨 𝐍𝐨𝐫𝐝𝐢𝐜 𝐋𝐢𝐟𝐞 𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞: Cure Parkinson's CEO Helen Matthews talks about their work, and participating in the International Linked Clinical Trials Initiative.
Full video: www.biotechtv.com/post/cure-pa...
Full video: www.biotechtv.com/post/cure-pa...
April 3, 2025 at 9:21 PM
𝐀𝐧𝐠𝐥𝐨 𝐍𝐨𝐫𝐝𝐢𝐜 𝐋𝐢𝐟𝐞 𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞: Cure Parkinson's CEO Helen Matthews talks about their work, and participating in the International Linked Clinical Trials Initiative.
Full video: www.biotechtv.com/post/cure-pa...
Full video: www.biotechtv.com/post/cure-pa...
𝐀𝐧𝐠𝐥𝐨 𝐍𝐨𝐫𝐝𝐢𝐜 𝐋𝐢𝐟𝐞 𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞: Denmark based Synklino is developing a fusion protein that targets US28 for CMV infections from transplants.
Full video: www.biotechtv.com/post/synklin...
Full video: www.biotechtv.com/post/synklin...
April 3, 2025 at 6:53 PM
𝐀𝐧𝐠𝐥𝐨 𝐍𝐨𝐫𝐝𝐢𝐜 𝐋𝐢𝐟𝐞 𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞: Denmark based Synklino is developing a fusion protein that targets US28 for CMV infections from transplants.
Full video: www.biotechtv.com/post/synklin...
Full video: www.biotechtv.com/post/synklin...
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: On the heels of raising a $65M series B, the CEO of Flagship's Ampersand Biomedicines describes the company's precision medicine platform, and gives updates on partnering and R&D progress.
Full video: www.biotechtv.com/post/ampersa...
Full video: www.biotechtv.com/post/ampersa...
April 3, 2025 at 11:16 AM
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: On the heels of raising a $65M series B, the CEO of Flagship's Ampersand Biomedicines describes the company's precision medicine platform, and gives updates on partnering and R&D progress.
Full video: www.biotechtv.com/post/ampersa...
Full video: www.biotechtv.com/post/ampersa...
𝐁𝐢𝐨𝐓𝐫𝐢𝐧𝐢𝐭𝐲 𝟐𝟎𝟐𝟓: With a novel E3 ubiquitin ligase (TRIM21) for protein degradation, Cambridge, UK based TRIMTECH Therapeutics recently raised a $31 million seed round.
Full video: www.biotechtv.com/post/trimtec...
Full video: www.biotechtv.com/post/trimtec...
April 2, 2025 at 1:16 PM
𝐁𝐢𝐨𝐓𝐫𝐢𝐧𝐢𝐭𝐲 𝟐𝟎𝟐𝟓: With a novel E3 ubiquitin ligase (TRIM21) for protein degradation, Cambridge, UK based TRIMTECH Therapeutics recently raised a $31 million seed round.
Full video: www.biotechtv.com/post/trimtec...
Full video: www.biotechtv.com/post/trimtec...
𝐁𝐫𝐢𝐠𝐡𝐭 𝐌𝐢𝐧𝐝𝐬: Vida Ventures named Matt Cohen and Brian Goodman new Managing Directors today. BiotechTV caught up with Brian in Vida's Boston office.
Full video: www.biotechtv.com/post/vida-ve...
Full video: www.biotechtv.com/post/vida-ve...
April 2, 2025 at 10:46 AM
𝐁𝐫𝐢𝐠𝐡𝐭 𝐌𝐢𝐧𝐝𝐬: Vida Ventures named Matt Cohen and Brian Goodman new Managing Directors today. BiotechTV caught up with Brian in Vida's Boston office.
Full video: www.biotechtv.com/post/vida-ve...
Full video: www.biotechtv.com/post/vida-ve...
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: After a $93M series B, Character Bio's CEO Cheng Zhang describes how the company has built a proprietary database to reclassify AMD patients into genetic subgroups to optimize trial patient selection.
Full video: www.biotechtv.com/post/charact...
Full video: www.biotechtv.com/post/charact...
April 2, 2025 at 2:54 AM
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: After a $93M series B, Character Bio's CEO Cheng Zhang describes how the company has built a proprietary database to reclassify AMD patients into genetic subgroups to optimize trial patient selection.
Full video: www.biotechtv.com/post/charact...
Full video: www.biotechtv.com/post/charact...
𝐓𝐡𝐞 𝐒𝐭𝐮𝐝𝐢𝐨 𝐚𝐭 𝐊𝐞𝐧𝐝𝐚𝐥𝐥 𝐒𝐪𝐮𝐚𝐫𝐞: Candel Therapeutics CEO Paul Peter Tak and IDEA Pharma CEO Mike Rea on why they believe a different mindset and good communication are keys to succeeding with new innovations in biotech.
Full video: www.biotechtv.com/post/the-stu...
Full video: www.biotechtv.com/post/the-stu...
April 2, 2025 at 12:28 AM
𝐓𝐡𝐞 𝐒𝐭𝐮𝐝𝐢𝐨 𝐚𝐭 𝐊𝐞𝐧𝐝𝐚𝐥𝐥 𝐒𝐪𝐮𝐚𝐫𝐞: Candel Therapeutics CEO Paul Peter Tak and IDEA Pharma CEO Mike Rea on why they believe a different mindset and good communication are keys to succeeding with new innovations in biotech.
Full video: www.biotechtv.com/post/the-stu...
Full video: www.biotechtv.com/post/the-stu...